European Commission grants approval of Ogsiveo (nirogacestat) for treatment of desmoid tumors – Merck
Merck KGaA, announced that the European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing… read more.
